Skip to main content
Equibles
PTPI logo

PTPI · Petros Pharmaceuticals, Inc. · Metrics

Track PTPI — free

Use PTPI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PTPI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.05 -0.02 (-28.79%) At close · May 22
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the Company does not have sufficient resources to fund its operations for the next twelve months from the date of this filing, management has substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$169,489
Shares
42.37M
Volume · May 22 10.28M Avg daily vol (16 sessions) 38.33M

PTPI metrics

47 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.05
Market cap
$169,489

Price action

20 metrics
Price change (1W)
-70.6%
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
13.1
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
42.37M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 18,468.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 3,016.2%
P / book
0.2
reciprocal yield 413.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,889.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.9×
reciprocal yield 53.4%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 53.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
76.3%
Operating margin
-90.5%
Trailing 12 months
Net margin
-280.1%
Gross profit (TTM)
$3.90M
Operating profit (TTM)
−$3.40M
Net income (TTM)
−$3.20M
Trailing 12 months
Diluted EPS (TTM)
$8.68
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$17.92
Gross profit per diluted share (TTM)
$13.67
Operating profit per diluted share (TTM)
$-0.08
EBITDA per diluted share (TTM)
$-7.23
Net income per diluted share (TTM)
$-0.07
Operating cash flow per diluted share (TTM)
$-0.08
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$11.17
Stock compensation per diluted share (TTM)
—
Book value per share
$0.07

Growth

11 metrics
Revenue growth YoY
-12.2%
Year over year
Net income growth YoY
-117.6%
Revenue (TTM)
$5.11M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+82.8%
Year over year · more shares
Revenue CAGR (3Y)
-13.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-456.8%
Return on assets
-90.3%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$1.80M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.49M
Total assets
$3.55M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.72M
Capital expenditures (TTM)
$4,633
R&D (TTM)
$2.62M
SG&A (TTM)
$3.40M
Stock compensation (TTM)
$388,500
R&D / revenue
51.2%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1815903 CUSIP 71678J308 Visit website Investor relations